Premium
Hemodialysis‐induced cardiovascular disease
Author(s) -
Ahmadmehrabi Shadi,
Tang W. H. Wilson
Publication year - 2018
Publication title -
seminars in dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 78
eISSN - 1525-139X
pISSN - 0894-0959
DOI - 10.1111/sdi.12694
Subject(s) - medicine , hemodialysis , kidney disease , disease , end stage renal disease , anemia , uremia , context (archaeology) , intensive care medicine , population , secondary hyperparathyroidism , cardiology , parathyroid hormone , paleontology , environmental health , biology , calcium
More than half of all deaths among end stage renal disease ( ESRD ) patients are due to cardiovascular disease ( CVD ). Cardiovascular changes secondary to renal dysfunction, including fluid overload, uremic cardiomyopathy, secondary hyperparathyroidism, anemia, altered lipid metabolism, and accumulation of gut microbiota‐derived uremic toxins like trimethylamine N ‐oxidase, contribute to the high risk for CVD in the ESRD population. In addition, conventional hemodialysis ( HD ) itself poses myocardial stress and injury on the already compromised cardiovascular system in uremic patients. This review will provide an overview of cardiovascular changes in chronic kidney disease and ESRD , a description of reported mechanisms for HD ‐induced myocardial injury, comparison of HD with other treatment modalities in the context of CVD , and possible management strategies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom